NCT04581629View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions

Autosomal Dominant Hypocalcemia (ADH)Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

DRUG

Encaleret

Tablets administered orally

Trial Locations (1)

20892

National Institutes of Health (NIH) Clinical Center, Bethesda

All Listed Sponsors

lead

Calcilytix Therapeutics, Inc., a BridgeBio company

INDUSTRY

NCT04581629 - Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 | Biotech Hunter | Biotech Hunter